HLS Therapeutics Inc.
HLTRF
$2.72
$0.082.96%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 56.24M | 55.74M | 55.50M | 55.85M | 56.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.24M | 55.74M | 55.50M | 55.85M | 56.42M |
| Cost of Revenue | 16.83M | 16.15M | 15.79M | 15.74M | 15.60M |
| Gross Profit | 39.41M | 39.59M | 39.71M | 40.11M | 40.82M |
| SG&A Expenses | 21.88M | 21.73M | 22.00M | 22.96M | 24.20M |
| Depreciation & Amortization | 22.04M | 21.99M | 21.82M | 21.79M | 21.79M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.75M | 59.87M | 59.61M | 60.49M | 61.58M |
| Operating Income | -4.51M | -4.13M | -4.11M | -4.64M | -5.16M |
| Income Before Tax | -9.22M | -10.71M | -12.88M | -13.83M | -14.80M |
| Income Tax Expenses | -649.00K | -420.00K | -445.00K | 287.00K | 245.00K |
| Earnings from Continuing Operations | -8.57 | -10.29 | -12.43 | -14.12 | -15.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.57M | -10.29M | -12.43M | -14.12M | -15.04M |
| EBIT | -4.51M | -4.13M | -4.11M | -4.64M | -5.16M |
| EBITDA | 17.01M | 17.35M | 17.19M | 16.67M | 16.15M |
| EPS Basic | -0.27 | -0.32 | -0.39 | -0.45 | -0.48 |
| Normalized Basic EPS | -0.18 | -0.21 | -0.25 | -0.28 | -0.29 |
| EPS Diluted | -0.27 | -0.33 | -0.39 | -0.46 | -0.49 |
| Normalized Diluted EPS | -0.18 | -0.21 | -0.25 | -0.28 | -0.29 |
| Average Basic Shares Outstanding | 127.33M | 127.69M | 128.21M | 125.07M | 125.46M |
| Average Diluted Shares Outstanding | 127.33M | 127.69M | 128.21M | 125.07M | 125.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |